Meeting
2014 Genitourinary Cancers Symposium
Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).
Authors
Himisha Beltran
Department of Medicine, Institute for Precision Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY
Himisha Beltran , Jessica Louw , Myriam Kossai , Rachel Krupa , Dena Marrinucci , Juan Miguel Mosquera , David M. Nanus , Scott T. Tagawa , Ryan Dittamore , Mark A. Rubin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 177)
DOI
10.1200/jco.2014.32.4_suppl.177
Abstract #
177
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
First Author: Joaquin Mateo
Poster
2021 Genitourinary Cancers Symposium
Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.
First Author: Morgan Goujon
Poster
2020 Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.
First Author: Di Maria Jiang
Poster
2019 ASCO Annual Meeting
Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC).
First Author: Valentino Cattori